Loading...
•
Jun 30, 2022
CRISPR Therapeutics Q2 2022 Earnings Report
CRISPR Therapeutics reported financial results for the second quarter ended June 30, 2022, and provided a business update.
Key Takeaways
CRISPR Therapeutics reported a collaboration revenue of $0.2 million for the second quarter of 2022, compared to $900.2 million for the second quarter of 2021. R&D expenses were $123.2 million, compared to $82.3 million for the second quarter of 2021. Net loss was $185.8 million for the second quarter of 2022, compared to net income of $759.2 million for the second quarter of 2021. Cash, cash equivalents and marketable securities were $2,073.7 million as of June 30, 2022, compared to $2,379.1 million as of December 31, 2021.
CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel) with the EMA and the MHRA; discussions with the FDA ongoing.
Initiated two additional Phase 3 clinical trials of exa-cel for the treatment of transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) in pediatric patients
Enrollment and dosing ongoing for CTX110, targeting CD19+ B-cell malignancies; expecting to report additional data in 2022
Enrollment and dosing ongoing for CTX130, targeting CD70 for the treatment of both solid tumors and certain hematologic malignancies
Forward Guidance
CRISPR Therapeutics expects to submit Investigational New Drug Applications (INDs) for two next generation chimeric antigen receptor T cell (CAR-T) candidates by year-end and to submit a Clinical Trials Application (CTA) for VCTX211 for the treatment of Type 1 Diabetes (T1D) in 2H 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...